23 results about "NITRIC OXIDE SYNTHASE 1" patented technology

The invention provides a tissue engineering heart valve stent with a sulfonated nano-enzyme coating as well as a preparation method and application of the tissue engineering heart valve stent, and belongs to the technical field of medical materials. The invention relates to a tissue engineering heart valve stent with a sulfonated nano-enzyme coating, which comprises an acellular matrix carrier, ruthenium / iridium-tannic acid nano-enzyme loaded on the acellular matrix carrier, and a sulfonated polymer coating fixed on the acellular matrix carrier and / or the surface of nano-particles through ultraviolet polymerization, the ruthenium / iridium-tannic acid nano-enzyme is formed by tannic acid TA, Ru < 3 + > and Ir < 3 + > through coordination. According to the invention, through double bionic activities of superoxide dismutase and nitric oxide synthase of ruthenium / iridium-tannic acid nano-enzyme and through the super-hydrophilicity and electrically neutral surface of the sulfonated polymer coating, collaborative regulation and control of O2-NO cascade catalysis and interface functions in a pathological microenvironment are realized; the structural and functional in-situ regeneration of the tissue engineering heart valve stent is promoted.

The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of Nos1 (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.

The invention relates to modulation of oral health by nitric oxide synthase pathways. Pharmaceutical compositions and methods for treating or preventing diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulating the nitric oxide synthase pathway are provided, as well as animal models and drug screening methods. This modulation may be accomplished by administering tetrahydrobiopterin (BH4), or a prodrug and / or salt thereof. Treatment and prevention of xerostomia may also have downstream effects of preventing periodontitis, decayed teeth, parotid gland enlargement, lip inflammation and dehiscence (cheilitis), tongue and buccal mucosa inflammation or ulcer, oral candidiasis, salivary gland infection (salivary adenitis), halitosis, and oral mucosa dehiscence and dehiscence.

The invention discloses an application of nitric oxide synthase neurons in an island leaf cortex II layer in preparation of a medicine for treating osteoporosis, and systematically reveals a nerve stress induced bone metabolism imbalance mechanism by constructing a chronic heterologous pressure stress mouse model and combining an enzyme-linked immunosorbent assay and a high-resolution micro-CT (Computed Tomography) technology; the method comprises the following steps: accurately positioning specific nerve connection between nNOS neurons of an island leaf cortex II layer and bone tissues for the first time by adopting a reverse cross-polysynaptic virus tracing technology, and determining that the region is a key central target point regulated and controlled by a brain-bone axis; the activity of target neurons is specifically intervened through a chemical genetics technology, it is proved that activation can induce the phenotype of osteoporosis, and pathologic indexes are remarkably improved through inhibition.

The invention belongs to the technical field of biological medicine, and particularly relates to coriaria sinica lactone compounds, a preparation method thereof and application of the coriaria sinica lactone compounds in anti-inflammatory activity. The coriaria sinica lactone compound can significantly inhibit a TLR4 / NF-kappa B signal channel to inhibit downstream inflammatory protein nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and further inhibit inflammatory BV2 cells from generating nitric oxide, the inhibition rate can reach 65.5%, and it is indicated that the coriaria sinica lactone compound has an application prospect in treatment of neuroinflammatory diseases.

The invention relates to application of 6 '-O-caffeoyl arbutin in preparation of a medicine for treating dementia, and belongs to the technical field of biological medicine. The 6 '-O-caffeoyl arbutin disclosed by the invention has a remarkable dementia treatment value, the action mechanism accurately fits the core pathological process of dementia, a neuroprotective effect is played by relieving oxidative stress and inhibiting inflammatory reaction, oxidative stress related indexes such as superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) can be effectively adjusted, and the dementia treatment effect is improved. The release of lactic dehydrogenase (LDH) and malondialdehyde (MDA) and the level of damage-induced nitric oxide synthase (I NOS) are reduced, so that the NMDA-induced PC12 cell damage is protected.

The application discloses a kind of micro bone-blood vessel symbiosis based on gene activation and its preparation method and application.The system includes: the amorphous calcium phosphate nanoparticles of L-arginine, bovine serum albumin and alendronate sodium co-modified loaded BMP-2 mRNA;Methacrylic acid gel hydrogel microspheres encapsulating the nanoparticle;And E7 peptide grafted on the surface of hydrogel microspheres.It is captured by E7 peptide bone marrow mesenchymal stem cells, and delivers BMP-2 mRNA to activate intracellular BMP-2 and endothelial-type nitric oxide synthase expression, while using L-arginine to drive in-situ synthesis of nitric oxide, to synergistically enhance stem cell osteogenic differentiation and promote vascular sprouting ability, realize the vascularization synchronous regeneration of bone defect.The system solves the problem of unstable exogenous nitric oxide donor and bone-vessel regeneration decoupling, and has excellent biocompatibility and bone repair efficiency.

The invention relates to a composition and a preparation method of a reproduction nursing external preparation with effects of inhibiting bacteria, relieving and improving male functions. The invention discloses an external preparation for male reproduction nursing. The plant essential oil comprises natural plant extracts (clove, herba epimedii, ginseng, dendrobium officinale, tribulus terrestris, radix sophorae flavescentis, fructus cnidii, saw palmetto fruit and aloe vera), nutritional ingredients (arginine, hydrolyzed collagen zinc, nicotinic acid, tocopherol, biotin and B-group vitamin yeast polypeptide) and compound essential oil (tea tree oil, jasmine flower oil, iris oil, cananga odorata flower oil and sandalwood oil). The composition can be prepared into spray, cream, lotion and other dosage forms. The preparation improves erectile function, enhances microcirculation, relieves pressure, improves sexual desire and realizes precise adjustment of male function and protection of gonad axis through mechanisms of inhibiting bacteria, diminishing inflammation, improving testosterone concentration, enhancing nitric oxide synthase activity, promoting vasodilatation, blocking neural signals, delaying ejaculation and the like.

The invention relates to the technical field of microbial infection treatment and molecular biology, and provides a method for inhibiting formation of a staphylococcus aureus biofilm, which is realized by inhibiting nitrosation modification of MgrA protein in staphylococcus aureus so as to inhibit formation of the biofilm. The inhibitor is nitric oxide synthase and is used for inhibiting nitrosation modification of the MgrA protein; the nitrosation modification for inhibiting the MgrA protein is realized by applying a nitric oxide synthase (NOS) inhibitor; the invention reveals that the staphylococcus aureus endogenous nitric oxide can promote the formation of a biofilm by modifying and regulating the 12th cysteine of the protein MgrA for the first time; based on the target spot, research proves that the MgrA modification level can be effectively reduced and the removal of the biofilm can be enhanced through multiple means such as gene mutation, NOS inhibitor or combination of the NOS inhibitor and antibiotics, and a new strategy and a potential drug development approach are provided for preventing and treating staphylococcus aureus intractable biofilm infection.

Preparation method and application of diterpenoid, relate to the application technical field of diterpenoid.The present application separates two new compounds of diterpenoid A and diterpenoid B from a strain of Hericium fermentation extract, and discloses chemical structural formula of the two compounds, and corresponding nuclear magnetic, mass spectrum, infrared and ultraviolet data, and its function of significantly inhibiting the production of inflammatory BV2 cell NO.Diterpenoid B has 24% of the promotion rate of axon growth of PC-12 cell, and simultaneously has significant inhibition of TLR4 / NF-κB signal path to inhibit downstream inflammatory proteins of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and diterpenoid A and diterpenoid B both show significant anti-neuroinflammatory activity.The present application can obtain the preparation method and application of diterpenoid.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

This invention discloses the application of Dendrobium huoshanense protocorms in anti-fatigue and kidney-tonifying and aphrodisiac effects. Combining Dendrobium huoshanense protocorms with Cistanche deserticola, American ginseng, Rubus idaeus, Cornus officinalis, and Lycium barbarum significantly enhances the anti-fatigue and kidney-tonifying and aphrodisiac effects of the formula. Compared with Cistanche deserticola alone, adding Dendrobium huoshanense protocorms significantly prolongs the exhaustive swimming time in mice, reduces serum urea nitrogen and lactic acid levels, increases liver glycogen content, and increases muscle glycogen content. Compared with Cistanche deserticola alone, adding Dendrobium huoshanense protocorms significantly increases serum superoxide dismutase activity, reduces serum malondialdehyde content, increases serum testosterone content, increases penile nitric oxide synthase activity, and increases penile nitric oxide and cyclic guanosine monophosphate content in penile tissue.

Microparticles that contain miRNA that controls the production of nitric oxide and are an agent for promoting the production of nitric oxide are new microparticles that enable controlling the expression of a protein and / or a gene related to erectile dysfunction; a preventive drug or a therapeutic drug for erectile dysfunction; a method for improving erectile dysfunction; it is preferable that the microparticles be exosomes; and it is preferable that the microparticles of the present disclosure contain miRNA targeting a gene concerning the expression of nitric oxide synthase as the miRNA that controls the production of nitric oxide, and be an agent for promoting the expression of nitric oxide synthase.

Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,where R5 isAt least one of R2-R4 or Re is halo.

The invention discloses a preparation method of alcohol-free extracted lavender polysaccharide and application of the alcohol-free extracted lavender polysaccharide in anti-aging products. The lavender polysaccharide (LAPC) is extracted from a lavender raw material by adopting a hot water extraction method in combination with a membrane separation technology, the yield is 4.8-8.6%, the polysaccharide content is 15-30%, the uronic acid content is 15-30%, and the pH value is 6.0-6.7. An anti-aging activity experiment in an aging mouse model induced by D-galactose shows that the LAPC prepared by the invention can remarkably improve the activity of antioxidant enzyme in an aging mouse body; the cell morphology of liver and kidney tissues is effectively improved; multiple serum biochemical indexes are recovered to be normal; the expression level of proinflammatory factors is reduced; the activity of acetylcholin esterase and nitric oxide synthase in brain tissues is inhibited; and the expression of a p53 / p21 protein signal channel is down-regulated. The LAPC provided by the invention has remarkable anti-aging activity. The provided preparation method of the lavender polysaccharide is simple, convenient and efficient, does not need complex chemical reagents, and has the potential of being developed into low-toxicity and efficient anti-aging cosmetics or medicine raw materials.

To provide a method for producing T cells for transplantation, by which T cells having an improved duration in vivo can be produced, to provide T cells having an improved duration in vivo, and to provide a pharmaceutical composition containing the T cells.SOLUTION: A method for producing a T cell for transplantation, comprising a step (A) of increasing an expression level of a nitric oxide synthase interacting protein in a T cell. There is also provided a T cell into which a nucleic acid having a function of improving an expression level of a nitric oxide synthase interacting protein is introduced.SELECTED DRAWING: None

The invention discloses a pyrimidine derivative or a pharmaceutically acceptable salt thereof. The general formula of the pyrimidine derivative is shown as a formula I; wherein n is 1 or 2, m is 0 or 1, and l is 1 or 2; x1 is selected from a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a halogen C1-C6 alkyl group, and a C3-C6 cycloalkyl group; in the formula, R3 is selected from H, halogen, nitryl, cyano, halogen C1-C6 alkyl and C1-C6 alkoxy; y1 and Y2 are independently selected from C, N, O and S; r1 and R2 are independently selected from H, halogen, nitryl, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halogen C1-C6 alkyl, C1-C6 alkoxy, carbamoyl and ester group. The compound can inhibit the inducible nitric oxide synthase and is used for preparing a medicine for inhibiting the inducible nitric oxide synthase.

The application discloses a one-oxygen-based fusion enzyme color developing agent and application. The color developing agent comprises a one-oxygen-based fusion enzyme, and the fusion enzyme is combined by a nitric oxide synthase, a flavoprotein and a flavoprotein reductase in sequence and two by two through a connecting peptide. The fusion enzyme provided by the application has high enzyme activity, can catalyze a large amount of one-oxygen, and can effectively combine myoglobin in meat products to generate nitroso-myoglobin, effectively improve the red color of the meat products, and obtain a color developing effect equivalent to that of sodium nitrite, thereby providing a very practically applicable solution for replacing the sodium nitrite color developing of the meat products and improving the safety of the meat products.

The invention provides a novel guanidino cyclohexane derivative as shown in a formula I, a preparation method of the novel guanidino cyclohexane derivative and application of a pharmaceutical preparation containing the novel guanidino cyclohexane derivative in drugs for treating gastric mucosal lesions. The compound has a medicine development prospect for preventing and treating reflux esophagitis by adjusting the influence of nitric oxide synthase (NOS) and anti-inflammatory activity on microcirculation.

This invention relates to a method of fixating and stabilizing nitric oxide metabolites through fermentation of nitrogen-containing natural substance. According to the method of the invention, the fermentation efficiency is maximized by optimizing the fermentation conditions so that the productivity of nitric oxide metabolites is significantly improved. Thus, eating a fermented natural substance in which nitric oxide metabolites are fixated and stabilized by the method of the present invention would be helpful for maintaining the homeostasis of human body, in which nitric oxide synthase is either absent or insufficient, based on vasodilation and activation of a neurotransmitter and immune function as medical efficacy of nitric oxide.

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.

The invention discloses a method for modifying human umbilical cord mesenchymal stem cells through nitric oxide synthase genes and application of the human umbilical cord mesenchymal stem cells. According to the method, the mesenchymal stem cells are modified by constructing a recombinant retroviral vector carrying a specific nitric oxide synthase gene (SEQ ID NO.1) and transfecting UCMSCs, so that the modified mesenchymal stem cells have remarkable effects in the aspects of repairing the penile erection function, improving the testosterone level and the like, and can be used for treating diabetic penile erection dysfunction.

The application provides a nano delivery system and a preparation method and application thereof. The delivery system comprises drug-loaded nanoparticles with a carboxylated shell, a recombinant red blood cell membrane layer coated on the surface of the drug-loaded nanoparticles, the recombinant red blood cell membrane layer is obtained by recombinant red blood cell membrane particles stimulated by lipopolysaccharide and polyethylene glycol derivatized phospholipid labeled with avidin, and can express endothelial type nitric oxide synthase; a polypeptide targeting placental chondroitin sulfate labeled with biotin also realizes the surface modification of the polypeptide to the recombinant red blood cell membrane layer through the specific binding of biotin and the avidin exposed outside the recombinant red blood cell membrane layer. The above-mentioned nano delivery system has good biocompatibility, can smoothly target placental trophoblasts, and after membrane fusion with the placental trophoblasts, in-situ releases NO and drug-loaded nanoparticles in the placental tissue, and has high clinical application value.